NCT00585416View on ClinicalTrials.gov

Study of CGC-11047 in Patients With Metastatic Hormone Refractory Prostate Cancer

PHASE2TerminatedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

June 30, 2006

Primary Completion Date

November 30, 2007

Study Completion Date

March 31, 2009

Conditions
Prostate Cancer
Interventions
DRUG

CGC-11047

CGC-11047 IV weekly for 3 weeks followed by one rest week (4weeks=1cycle)

Trial Locations (1)

53792

University of Wisconsin Hospital and Clinics, Madison

Sponsors

Collaborators (1)

Progen Pharmaceuticals
All Listed Sponsors
collaborator

Progen Pharmaceuticals

INDUSTRY

lead

University of Wisconsin, Madison

OTHER